Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Sep 4, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called Pediatric Systemic Lupus Erythematosus (SLE), which is an autoimmune disease that can affect children and teenagers. Specifically, the researchers want to understand how a part of the immune system, called the interferon type I pathway, is involved in SLE, especially in cases where the kidneys are affected. They are interested in whether certain genetic forms of SLE lead to stronger activation of this pathway, which has not been studied in children before.

To be eligible for this trial, participants must have been diagnosed with SLE before turning 18 years old and show signs of kidney involvement related to the disease. They will not be able to join if their kidney issues started after they turned 18 or if their SLE is caused by other conditions or medications. Those who take part can expect to contribute to important research that could help improve understanding and treatment of pediatric SLE. The trial is currently recruiting participants of all genders, and it aims to gather valuable insights that could benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of SLE arising before the age of majority (until the age of 18 years) according to SLICC and/or EULAR criteria 2019;
• • Clinical, laboratory and/or histologic evidence of renal involvement manifested before the age of 18 years;
• • Signature of informed consent.
• Exclusion Criteria:
• • Onset of renal disease after the age of 18 years;
• • SLE secondary to drugs or associated with other diseases such as systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, and other connectivities.